On Friday, Shares of Whiting Petroleum Corp (NYSE:WLL), added 1.16% and closed at $8.74 in the last trading session. The last trading range of the stock ranges between $8.51 and $8.94. Whiting Petroleum Corporation, a Delaware corporation, is an independent oil and gas company that explores for, develops, acquires and produces crude oil, natural gas and natural gas liquids mainly in the Rocky Mountain region of the United States. The Company’s leading projects are in the Bakken and Three Forks plays in North Dakota and Niobrara play in northeast Colorado. The Company trades publicly under the symbol WLL on the New York Stock Exchange.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), jumped 14.02% and closed at $3.01 in the last trading session. The last trading range of the stock ranges between $2.93 and $3.72. The company’s Market capitalization is $106.22 million with the total Outstanding Shares of 35.29 million. Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, recently declared that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group. These pre-specified endpoints include: Partial Remission (PR), which is measured by a ≥50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the 24-week treatment period.
The AURA-LV study remains ongoing to its 48-week endpoint upon which similar and additional secondary analysis will be analysed and presented early next year.
“We are thrilled by the results of the AURA study and voclosporin’s potential to shift the treatment paradigm for active lupus nephritis,” said Charles Rowland, CEO of Aurinia. “The ability to get more patients into remission and in a shorter period time than the current standard of care can have a noteworthyimpact on the long-term outcomes for these patients.”
“LN is a serious and devastating disease that can severely impact a patient’s life,” said William Pendergraft, MD, PhD, Assistant Professor of Medicine in the Division of Nephrology & Hypertension, at the University of North Carolina and a Principal Investigator in the study. “Voclosporin has demonstrated it can nearly double the number of patients that achieve Complete Remission in the presence of very low corticosteroid exposure. Based on these data, I believe this drug has the potential to significantly improve the long-term prognosis of my patients afflicted with LN and could become an integral component of the standard of care.”